# SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC（SYNSTAR 04）

> **NCT07633873** · PHASE3 · NOT_YET_RECRUITING · sponsor: **CSPC Megalith Biopharmaceutical Co.,Ltd.** · enrollment: 500 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** SYS6010 injection
- **DRUG:** Enlonstobart injection
- **DRUG:** Tislelizumab injection
- **DRUG:** Paclitaxel+Carboplatin or Pemetrexed + Cisplatin/Carboplatin

## Key facts

- **NCT ID:** NCT07633873
- **Lead sponsor:** CSPC Megalith Biopharmaceutical Co.,Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-02
- **Primary completion:** 2027-09-30
- **Final completion:** 2029-05-30
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2026-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07633873

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07633873, "SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC（SYNSTAR 04）". Retrieved via MORVS 2026-10-23 from https://api.morvs.ai/clinical/NCT07633873. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*